Weak Fundamental Momentum Sinks Atyr Pharma Inc

EVTL

Atyr Pharma Inc (NASDAQ:ATYR) has a beta value of 1.20 and has seen 5.67 million shares traded in the last trading session. The company, currently valued at $169.79M, closed the last trade at $2.24 per share which meant it gained $0.01 on the day or 0.45% during that session. The ATYR stock price is -11.61% off its 52-week high price of $2.50 and 51.79% above the 52-week low of $1.08. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.39 million shares traded. The 3-month trading volume is 453.73K shares.

Atyr Pharma Inc (NASDAQ:ATYR) trade information

Sporting 0.45% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ATYR stock price touched $2.24 or saw a rise of 2.61%. Year-to-date, Atyr Pharma Inc shares have moved 58.87%, while the 5-day performance has seen it change 18.52%. Over the past 30 days, the shares of Atyr Pharma Inc (NASDAQ:ATYR) have changed 17.89%. Short interest in the company has seen 1.36 million shares shorted with days to cover at 4.1.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Atyr Pharma Inc (ATYR) estimates and forecasts

Figures show that Atyr Pharma Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 31.76% over the past 6 months, with this year growth rate of 3.19%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be -32.00%.

6 analysts offering their estimates for the company have set an average revenue estimate of 20k for the current quarter. 6 have an estimated revenue figure of 20k for the next ending quarter.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 43.36% over the past 5 years. Earnings growth for 2024 is a modest 5.62% while over the next 5 years, the company’s earnings are expected to increase by 13.00%.

ATYR Dividends

Atyr Pharma Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Also the top two Mutual Funds that are holding company’s shares are Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund . As of Jul 31, 2024 , the former fund manager holds about 10.36% shares in the company for having 7.85 shares of worth $17.58 million while later fund manager owns 6.62 shares of worth $14.83 million as of Jul 31, 2024 , which makes it owner of about 8.73% of company’s outstanding stock.